PERSONAL INFORMATION
Name: Sirong He
Gender: Male
Title: Associate Professor
Position: Deputy Director.
CONTACT INFORMATION
Email: hesirong@cqmu.edu.cn
Phone: +86-13438020141
EDUCATION EXPERIENCE
September 2011- May 2014, Doctor of Medical Immunology, West China Hospital, Sichuan University;
September 2008 to June 2011: Master's degree in Clinical Medicine (Transplantation Science and Engineering), West China Hospital, Sichuan University;
September 2002- June 2007, Bachelor of Preventive Medicine, Sichuan University.
WORKING EXPERIENCE
June 2014 to present, Associate Professor and Master's Supervisor at Chongqing Medical University;
July 2007 to December 2008, physician, Hunan Xiangxi Center for Disease Control and Prevention.
RESEARCH INTERESTS
1) Research on immunotherapy drugs: research and development of bispecific antibodies, antibody conjugated drugs, cellular immunotherapy products, new recombinant/mRNA vaccines, etc;
2) High throughput detection technology: clinical application of second-generation gene sequencing technology and single-cell sequencing technology, joint analysis of pathological characteristics and immune function detection of major diseases, research on human immune tissue library, rapid screening of immunotherapy advantage targets and drugs, etc;
3) Preclinical evaluation of drugs: Research on non human primate disease models and preclinical pharmacodynamic evaluation. Using primate models, I was responsible for two preclinical trial projects: "CTLA-4Ig gene therapy at immune checkpoint (Xiangya Third Hospital of Central South University)" and "autologous bone marrow mesenchymal stem cell therapy (West China Hospital of Sichuan University)".
PUBLICATIONS
1) Bai X, Wang D, Wang B, Zhang X, Bai Y, Zhang X, Tian R, Li C, Yi Q, Cheng Y, He S. Staphylococcal protein A-modified hydrogel facilitates in situ immunomodulation by capturing anti-HMGB1 for islet grafts. Acta Biomater. 2023 Aug;166:95-108.
2) He S, Tian R, Zhang X, Yao Q, Chen Q, Liu B, Liao L, Gong Y, Yang H, Wang D. PPARγ inhibits small airway remodeling through mediating the polarization homeostasis of alveolar macrophages in COPD. Clin Immunol. 2023 May;250:109293.
3) Wang D, Bai X, Wang B, Yi Q, Yu W, Zhang X, Tian R, Zhang X, Li C, Chen Y, Liu Y, Cheng Y, He S. CTLA4Ig/VISTAIg combination therapy selectively induces CD4+ T cell-mediated immune tolerance by targeting the SOCS1 signaling pathway in porcine islet xenotransplantation. Immunology. 2022 Jun;166(2):169-184.
4) He S, Xia J, Zhang W, Lai M, Cheng N, Liu Z, Cheng Y. Prophylactic abdominal drainage for pancreatic surgery. Cochrane Database Syst Rev. 2021 Dec 18;12(12):CD010583.
5) He S, Wang C, Du X, Chen Y, Zhao J, Tian B, Lu H, Zhang Y, Liu J, Yang G, Li L, Li H, Cheng J, Lu Y. MSCs promote the development and improve the function of neonatal porcine islet grafts. FASEB J. 2018 Jun;32(6):3242-3253.
6) Cheng Y, Wang D, Wang B, Li H, Xiong J, Xu S, Chen Q, Tao K, Yang X, Zhu Y, He S. HMGB1 translocation and release mediate cigarette smoke-induced pulmonary inflammation in mice through a TLR4/MyD88-dependent signaling pathway. Mol Biol Cell. 2017 Jan 1;28(1):201-209.
7) Cheng Y, Xiong J, Chen Q, Xia J, Zhang Y, Yang X, Tao K, Zhang S, He S. Hypoxia/reoxygenation-induced HMGB1 translocation and release promotes islet proinflammatory cytokine production and early islet graft failure through TLRs signaling. Biochim Biophys Acta Mol Basis Dis. 2017 Feb;1863(2):354-364.
8) Cheng Y, Xia J, Lai M, Cheng N, He S. Prophylactic abdominal drainage for pancreatic surgery. Cochrane Database Syst Rev. 2016 Oct 21;10(10):CD010583.
9) He S, Zhang Y, Wang D, Tao K, Zhang S, Wei L, Chen Q. Rapamycin/GABA combination treatment ameliorates diabetes in NOD mice. Mol Immunol. 2016 May;73:130-7.
